KR100616028B1 - 인자 ⅷ을 위한 발현 시스템 - Google Patents

인자 ⅷ을 위한 발현 시스템 Download PDF

Info

Publication number
KR100616028B1
KR100616028B1 KR1020017007149A KR20017007149A KR100616028B1 KR 100616028 B1 KR100616028 B1 KR 100616028B1 KR 1020017007149 A KR1020017007149 A KR 1020017007149A KR 20017007149 A KR20017007149 A KR 20017007149A KR 100616028 B1 KR100616028 B1 KR 100616028B1
Authority
KR
South Korea
Prior art keywords
leu
ser
protein
delete delete
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020017007149A
Other languages
English (en)
Korean (ko)
Other versions
KR20020013481A (ko
Inventor
명-삼 조
샴 유엔 챈
윌리암 켈시
헬레나 이
Original Assignee
바이엘 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 코포레이션 filed Critical 바이엘 코포레이션
Publication of KR20020013481A publication Critical patent/KR20020013481A/ko
Application granted granted Critical
Publication of KR100616028B1 publication Critical patent/KR100616028B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
KR1020017007149A 1998-12-10 1999-12-08 인자 ⅷ을 위한 발현 시스템 Expired - Lifetime KR100616028B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
US09/209,916 1998-12-10

Publications (2)

Publication Number Publication Date
KR20020013481A KR20020013481A (ko) 2002-02-20
KR100616028B1 true KR100616028B1 (ko) 2006-08-28

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007149A Expired - Lifetime KR100616028B1 (ko) 1998-12-10 1999-12-08 인자 ⅷ을 위한 발현 시스템

Country Status (26)

Country Link
US (10) US6358703B1 (cg-RX-API-DMAC7.html)
EP (1) EP1137797B1 (cg-RX-API-DMAC7.html)
JP (1) JP4240818B2 (cg-RX-API-DMAC7.html)
KR (1) KR100616028B1 (cg-RX-API-DMAC7.html)
AT (1) ATE412765T1 (cg-RX-API-DMAC7.html)
AU (1) AU761801B2 (cg-RX-API-DMAC7.html)
BG (1) BG65431B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI9916069B8 (cg-RX-API-DMAC7.html)
CA (1) CA2354845C (cg-RX-API-DMAC7.html)
CZ (1) CZ302330B6 (cg-RX-API-DMAC7.html)
DE (1) DE69939839D1 (cg-RX-API-DMAC7.html)
DK (1) DK1137797T3 (cg-RX-API-DMAC7.html)
ES (1) ES2315026T3 (cg-RX-API-DMAC7.html)
HU (1) HU228489B1 (cg-RX-API-DMAC7.html)
IL (2) IL143353A0 (cg-RX-API-DMAC7.html)
NO (1) NO329544B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ512234A (cg-RX-API-DMAC7.html)
PL (1) PL200676B1 (cg-RX-API-DMAC7.html)
PT (1) PT1137797E (cg-RX-API-DMAC7.html)
RO (1) RO121604B1 (cg-RX-API-DMAC7.html)
RU (1) RU2249041C2 (cg-RX-API-DMAC7.html)
SI (1) SI20644B (cg-RX-API-DMAC7.html)
SK (1) SK286945B6 (cg-RX-API-DMAC7.html)
TR (1) TR200101592T2 (cg-RX-API-DMAC7.html)
UA (1) UA77383C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000034505A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125999A3 (en) * 2008-04-12 2010-01-14 Celltrion, Inc. Human host cell for producing recombinant proteins with high quality and quantity

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
EP1421539B1 (en) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
CA2728708A1 (en) * 2008-06-25 2009-12-30 Bayer Healthcare Llc Factor viii muteins with reduced immunogenicity
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
KR101691070B1 (ko) * 2008-09-03 2016-12-29 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
RU2600886C2 (ru) * 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
WO2018017923A1 (en) 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612213A (en) * 1993-06-10 1997-03-18 Bayer Corporation Method of selecting mammalian cell lines having improved productivity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
DE3769872D1 (de) * 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE69027683T2 (de) * 1989-12-01 1997-02-13 Pharming Bv Herstellung rekombinanter polypeptide durch rinder und transgene methoden
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612213A (en) * 1993-06-10 1997-03-18 Bayer Corporation Method of selecting mammalian cell lines having improved productivity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125999A3 (en) * 2008-04-12 2010-01-14 Celltrion, Inc. Human host cell for producing recombinant proteins with high quality and quantity

Also Published As

Publication number Publication date
NO329544B1 (no) 2010-11-08
AU761801B2 (en) 2003-06-12
NZ512234A (en) 2002-12-20
US20090036358A1 (en) 2009-02-05
WO2000034505A1 (en) 2000-06-15
SI20644B (sl) 2009-04-30
BR9916069A (pt) 2001-09-04
ES2315026T3 (es) 2009-03-16
US8945869B2 (en) 2015-02-03
BRPI9916069B1 (pt) 2016-08-02
EP1137797B1 (en) 2008-10-29
US20160115219A1 (en) 2016-04-28
IL143353A (en) 2010-12-30
CA2354845A1 (en) 2000-06-15
SI20644A (sl) 2002-02-28
US8207117B2 (en) 2012-06-26
US9249209B2 (en) 2016-02-02
JP2002531137A (ja) 2002-09-24
US20030077752A1 (en) 2003-04-24
US9650431B2 (en) 2017-05-16
PT1137797E (pt) 2008-12-26
BRPI9916069B8 (pt) 2021-05-25
US6358703B1 (en) 2002-03-19
DE69939839D1 (de) 2008-12-11
HUP0200558A2 (en) 2002-06-28
US20020102730A1 (en) 2002-08-01
RU2249041C2 (ru) 2005-03-27
US20020115152A1 (en) 2002-08-22
ATE412765T1 (de) 2008-11-15
CZ20012024A3 (cs) 2001-10-17
RO121604B1 (ro) 2007-12-28
US20130143818A1 (en) 2013-06-06
US20130267468A1 (en) 2013-10-10
US7459525B2 (en) 2008-12-02
SK286945B6 (sk) 2009-08-06
DK1137797T3 (da) 2009-02-23
CZ302330B6 (cs) 2011-03-16
CA2354845C (en) 2008-08-12
US20110144025A1 (en) 2011-06-16
UA77383C2 (uk) 2006-12-15
JP4240818B2 (ja) 2009-03-18
AU2170100A (en) 2000-06-26
PL349284A1 (en) 2002-07-15
BG65431B1 (bg) 2008-07-31
TR200101592T2 (tr) 2001-11-21
PL200676B1 (pl) 2009-01-30
US20170267745A1 (en) 2017-09-21
BG105567A (en) 2002-03-29
NO20012718D0 (no) 2001-06-01
SK7922001A3 (en) 2002-01-07
EP1137797A4 (en) 2005-06-22
EP1137797A1 (en) 2001-10-04
KR20020013481A (ko) 2002-02-20
HU228489B1 (en) 2013-03-28
HUP0200558A3 (en) 2004-11-29
NO20012718L (no) 2001-06-01
IL143353A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
KR20020013481A (ko) 인자 ⅷ을 위한 발현 시스템
EP0306968B1 (en) Process for producing recombinant human factor VIII:C
EP0506757B2 (en) A recombinant human factor viii derivative
US6171825B1 (en) Preparation of recombinant factor VIII in a protein free medium
JP4124493B2 (ja) 無血清培地
WO1990002175A1 (en) A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
CN1265144A (zh) 鉴定可用于通过内源基因激活生产人蛋白质的人细胞系
EP1673391B1 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
MXPA01005667A (en) Expression system for factor viii
EP1318198B1 (en) Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
MXPA98003051A (en) Preparation of recombinant factor viii in a protei free medium

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20041118

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060803

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060818

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060821

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090813

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100809

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110809

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20120806

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20120806

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130808

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140805

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140805

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150805

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150805

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160808

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160808

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170804

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180730

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180730

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190729

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190729

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20200608

Termination category: Expiration of duration